What the business is, and whether it's a good one at a fair price.
Markets and distributes advanced medical imaging and neurosurgical technologies through subsidiaries and associates. Its wholly-owned subsidiary Time Medical International Ventures (India) supplies MRI systems, intraoperative MRI suites (including the AI-enabled DRIS-iMRI Medharanya Suite for neurosurgery combining AR, AI, ML and Exoscope technologies), Exoscope systems, and brain aneurysm screening solutions. Through associate Nanomedic Technologies, it holds exclusive India and Southeast Asia distribution rights for the Spincare portable electrospun wound care system, which received CDSCO import approval as India's first such clearance for a portable electrospun wound care device. The company operates as a single reportable segment under Ind AS 108, and reported FY26 revenue of Rs. 308.58 crore with net profit of Rs. 31.02 crore. A partnership with the WFNS Innovation & Technology Committee, the first such formal industry tie-up in the committee's history, supports global training and knowledge-sharing in neurosurgical technologies. On the cost side, materials account for 20.2% of revenue and other operating expenses for 34.9%, with employee cost at 4.9% and depreciation at 1.0%. A Rs. 358.46 crore preferential issue has funded imaging technology growth and general corporate purposes, with Rs. 280.93 crore deployed by March 2026.
Measured from the filed financials, judged against its Medical Equipment & Supplies peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from FISCHER MEDICAL VENTURE L's filed financials and exchange disclosures
FISCHER MEDICAL VENTURE L is a Healthcare Equipment & Supplies company listed on NSE and BSE, trading under the symbol FISCHER.
Yes. Over the trailing twelve months FISCHER MEDICAL VENTURE L reported a net profit of ₹30 Cr on revenue of ₹367 Cr.
Yes. The dividend yield is 0.01% at the current price. It paid out 1% of its profit as dividend in FY26.
No. Debt stands at 0.19× equity, and it carries net debt of ₹60 Cr. That is lower than 30% of its 11 Medical Equipment & Supplies peers.
On trailing P/E, FISCHER MEDICAL VENTURE L ranks 6 of 17 in Medical Equipment & Supplies — cheaper than 69% of them, against an industry median of 20.0×. This is a position, not a valuation judgement.
On a typical session FISCHER MEDICAL VENTURE L moves 1.94% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by FISCHER MEDICAL VENTURE L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
